A Phase 1 interventional study of Inclisiran formulation containing PS80 and Currently marketed inclisiran formulation in Inclisiran Formulation, sponsored by Novartis Pharmaceuticals. Recruiting at 6 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the currently marketed formulation of inclisiran with a new formulation containing polysorbate 80 (PS80), after a single 284 mg subcutaneous (SC) administration.
This is a randomized, single-dose, open-label, parallel-group, study to evaluate the PK, safety, and tolerability of inclisiran 284 mg. The study drug will be administered as a single SC injection to the abdomen administered as 2 different formulations (the marketed formulation and a test formulation containing PS80). Approximately 152 adult participants (76 per formulation) with elevated serum LDL-C, but otherwise healthy, are planned to be enrolled.
The duration of the study for each participant will be approximately 118 days including the screening, up to 28 days, baseline period, and treatment period of 90 days.
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inclisiran 284 mg × 1 single dose on Day 1
Drug: Currently marketed inclisiran formulation
Inclisiran 284 mg × 1 single dose on Day 1
Drug: Inclisiran formulation containing PS80
Inclisiran 284 mg
Also known as: KJX839
Inclisiran 284 mg
Also known as: KJX839
Primary plasma PK parameters: Cmax
Cmax = maximum observed plasma concentration
Time frame: Day 1, Day 2, Day 3 and Day 4
Primary plasma PK parameters: AUClast
AUClast = AUC from time zero to the last measurable concentration sampling time
Time frame: Day 1, Day 2, Day 3 and Day 4
Primary plasma PK parameters: AUCinf
AUCinf = AUC from time zero to infinity
Time frame: Day 1, Day 2, Day 3 and Day 4
Additional PK parameters: AUC0-24hr
AUC0-24hr = AUC from time zero to 24 hours
Time frame: Day 1, Day 2, Day 3 and Day 4
Additional PK parameters: Tmax
Tmax = time to reach maximum plasma concentration
Time frame: Day 1, Day 2, Day 3 and Day 4
Additional PK parameters: T1/2
T1/2 = elimination half-life
Time frame: Day 1, Day 2, Day 3 and Day 4
Additional PK parameters: CL/F
CL/F = total body clearance
Time frame: Day 1, Day 2, Day 3 and Day 4
Additional PK parameters: Vz/F
Vz/F = apparent volume of distribution
Time frame: Day 1, Day 2, Day 3 and Day 4
Number of participants with AEs
Number of participants with AEs, including abnormal vital signs, ECGs, injection site reactions and safety laboratory parameters.
Time frame: Up to Day 90
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclisiran